MeSH term
Frequency | Condition_Probility | Adult | 75 | 0.0 |
Aged | 64 | 0.0 |
Aged, 80 and over | 26 | 0.0 |
Comparative Study | 35 | 0.0 |
Female | 121 | 0.0 |
Humans | 318 | 0.0 |
Immunoenzyme Techniques | 3 | 0.0 |
Lymphatic Metastasis | 5 | 0.0 |
Male | 108 | 0.0 |
Middle Aged | 87 | 0.0 |
Neoplasm Invasiveness | 4 | 0.0 |
Neoplasm Staging | 6 | 0.0 |
O(6)-Methylguanine-DNA Methyltransferase/*metabolism | 14 | 77.0 |
Research Support, Non-U.S. Gov't | 228 | 0.0 |
Smoking/*metabolism | 2 | 4.0 |
Up-Regulation | 3 | 0.0 |
Alleles | 7 | 0.0 |
Cell Transformation, Neoplastic/genetics | 3 | 1.0 |
Child | 23 | 0.0 |
Child, Preschool | 19 | 0.0 |
*DNA Methylation | 83 | 12.0 |
DNA, Neoplasm/chemistry/genetics | 2 | 1.0 |
Gene Expression Profiling | 4 | 0.0 |
*Gene Expression Regulation, Neoplastic | 13 | 0.0 |
*Gene Silencing | 4 | 2.0 |
*Genes, Tumor Suppressor | 7 | 0.0 |
Infant | 10 | 0.0 |
Neoplasm Proteins/biosynthesis/*genetics | 2 | 2.0 |
Polymerase Chain Reaction | 46 | 0.0 |
Promoter Regions (Genetics)/*genetics | 14 | 1.0 |
Research Support, U.S. Gov't, P.H.S. | 124 | 0.0 |
Tumor Cells, Cultured | 64 | 0.0 |
*Tumor Suppressor Proteins | 7 | 0.0 |
Adolescent | 26 | 0.0 |
Base Sequence | 40 | 0.0 |
DNA Primers | 8 | 0.0 |
DNA Repair/*genetics | 11 | 3.0 |
*Genes, p53 | 6 | 1.0 |
Infant, Newborn | 2 | 0.0 |
Mutation | 20 | 0.0 |
O(6)-Methylguanine-DNA Methyltransferase/*genetics | 28 | 87.0 |
Polymorphism, Single-Stranded Conformational | 6 | 0.0 |
Animals | 86 | 0.0 |
Antineoplastic Agents/*pharmacology | 17 | 1.0 |
Blotting, Northern | 14 | 0.0 |
*Drug Resistance, Neoplasm | 6 | 3.0 |
Glutathione Transferase/metabolism | 3 | 0.0 |
Mice | 53 | 0.0 |
Mice, Inbred BALB C | 8 | 0.0 |
Neoplasm Transplantation | 11 | 0.0 |
O(6)-Methylguanine-DNA Methyltransferase/metabolism | 4 | 28.0 |
P-Glycoprotein/metabolism | 2 | 3.0 |
Blotting, Western | 29 | 0.0 |
CpG Islands/genetics | 5 | 3.0 |
DNA, Neoplasm/metabolism | 5 | 3.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Gene Silencing | 11 | 3.0 |
Ligases/genetics/metabolism | 2 | 8.0 |
O(6)-Methylguanine-DNA Methyltransferase/*genetics/*metabolism | 6 | 100.0 |
*Promoter Regions (Genetics) | 18 | 0.0 |
RNA, Messenger/metabolism | 8 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 19 | 0.0 |
Biopsy | 6 | 0.0 |
Case-Control Studies | 6 | 0.0 |
Cell Transformation, Neoplastic | 4 | 0.0 |
Disease Progression | 10 | 0.0 |
Promoter Regions (Genetics) | 39 | 0.0 |
Transcription, Genetic | 16 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Carcinoma, Non-Small-Cell Lung/*genetics | 3 | 4.0 |
DNA, Neoplasm/*analysis | 2 | 1.0 |
Gene Expression Regulation, Neoplastic/genetics | 2 | 1.0 |
Genetic Markers | 3 | 0.0 |
Lung Neoplasms/*genetics | 3 | 1.0 |
Tumor Markers, Biological/*analysis | 3 | 0.0 |
CpG Islands/*genetics | 12 | 12.0 |
DNA, Neoplasm/*genetics | 7 | 3.0 |
Immunohistochemistry | 21 | 0.0 |
CpG Islands | 20 | 7.0 |
DNA Methylation | 19 | 2.0 |
Prognosis | 12 | 0.0 |
Smoking/*adverse effects | 2 | 0.0 |
Survival Rate | 8 | 0.0 |
Protein p16/metabolism | 2 | 3.0 |
Sensitivity and Specificity | 3 | 0.0 |
Astrocytoma/*genetics | 3 | 6.0 |
Brain Neoplasms/*genetics | 2 | 1.0 |
Cadherins/metabolism | 2 | 1.0 |
DNA-Binding Proteins/metabolism | 3 | 0.0 |
Epigenesis, Genetic | 2 | 7.0 |
Neoplasm Proteins/*metabolism | 2 | 0.0 |
Sex Factors | 2 | 0.0 |
Loss of Heterozygosity | 6 | 0.0 |
English Abstract | 14 | 0.0 |
Follow-Up Studies | 5 | 0.0 |
Gene Expression Regulation, Neoplastic | 16 | 0.0 |
Cell Division | 7 | 0.0 |
Cell Line | 24 | 0.0 |
Electrophoresis, Agar Gel | 2 | 0.0 |
Flow Cytometry | 4 | 0.0 |
Transfection | 25 | 0.0 |
Adenocarcinoma/genetics | 2 | 2.0 |
Colorectal Neoplasms/*genetics | 3 | 1.0 |
Microsatellite Repeats/*genetics | 3 | 1.0 |
Phenotype | 10 | 0.0 |
Brain/enzymology | 3 | 1.0 |
DNA Damage | 8 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Enzyme Induction | 3 | 0.0 |
Guanine/*analogs & derivatives/analysis | 2 | 40.0 |
Liver/enzymology | 2 | 0.0 |
Mice, Inbred C3H | 7 | 1.0 |
Mice, Inbred C57BL | 9 | 0.0 |
Mice, Transgenic | 11 | 0.0 |
O(6)-Methylguanine-DNA Methyltransferase/genetics/*physiology | 3 | 50.0 |
Recombinant Fusion Proteins/physiology | 2 | 0.0 |
Transferrin/genetics | 2 | 4.0 |
Transgenes | 3 | 0.0 |
Drug Evaluation | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 5 | 0.0 |
Glutathione/metabolism | 3 | 1.0 |
O(6)-Methylguanine-DNA Methyltransferase/genetics/*metabolism | 10 | 90.0 |
Plasmids | 5 | 0.0 |
Protein p53/metabolism | 2 | 0.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/genetics | 6 | 25.0 |
DNA Primers/chemistry | 6 | 0.0 |
Gene Expression | 14 | 0.0 |
Glutathione Transferase/genetics | 7 | 2.0 |
Isoenzymes/genetics | 7 | 2.0 |
O(6)-Methylguanine-DNA Methyltransferase/genetics | 17 | 60.0 |
Protein p16/genetics | 8 | 9.0 |
Receptors, Retinoic Acid/genetics | 5 | 5.0 |
Transcription Factors/genetics | 2 | 0.0 |
Transplantation, Heterologous | 11 | 1.0 |
Antineoplastic Agents/*therapeutic use | 8 | 2.0 |
*DNA Helicases | 3 | 1.0 |
DNA Repair/genetics | 8 | 4.0 |
DNA-Binding Proteins/genetics | 6 | 0.0 |
Gene Expression Regulation, Neoplastic/drug effects | 2 | 0.0 |
HT29 Cells | 3 | 1.0 |
Mice, Nude | 14 | 0.0 |
*Organic Cation Transport Proteins | 4 | 14.0 |
Proteins/genetics | 3 | 0.0 |
RNA, Neoplasm/genetics/metabolism | 2 | 1.0 |
*Transcription Factors | 3 | 0.0 |
Xenograft Model Antitumor Assays | 3 | 1.0 |
Point Mutation | 6 | 0.0 |
Analysis of Variance | 2 | 0.0 |
Colorectal Neoplasms/enzymology | 2 | 66.0 |
Immunohistochemistry/methods | 2 | 0.0 |
Liver Neoplasms/*enzymology | 2 | 8.0 |
Neoplasm Proteins/*analysis | 2 | 0.0 |
O(6)-Methylguanine-DNA Methyltransferase/*analysis | 3 | 75.0 |
Survival Analysis | 13 | 0.0 |
Genes, Tumor Suppressor | 10 | 1.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
DNA, Neoplasm/genetics | 3 | 0.0 |
Gene Expression Regulation, Enzymologic | 11 | 1.0 |
Genes, p53/*genetics | 2 | 0.0 |
*Mutation | 11 | 0.0 |
Cell Survival/drug effects | 12 | 1.0 |
Drug Resistance, Neoplasm | 13 | 2.0 |
Genetic Vectors | 9 | 0.0 |
Hela Cells | 21 | 0.0 |
Nimustine/*pharmacology | 5 | 83.0 |
O(6)-Methylguanine-DNA Methyltransferase/*genetics/metabolism | 6 | 42.0 |
RNA, Messenger/genetics | 8 | 0.0 |
Retroviridae/genetics | 3 | 0.0 |
Solubility | 2 | 0.0 |
Structure-Activity Relationship | 4 | 0.0 |
Cloning, Molecular | 10 | 0.0 |
*DNA Repair | 23 | 3.0 |
Escherichia coli/genetics | 3 | 0.0 |
O(6)-Methylguanine-DNA Methyltransferase/*genetics/pharmacology | 2 | 66.0 |
Lymphoma/*genetics | 2 | 4.0 |
Mass Screening | 2 | 1.0 |
DNA Mutational Analysis | 5 | 0.0 |
Promoter Regions (Genetics)/genetics | 9 | 0.0 |
Proto-Oncogene Proteins B-raf/*genetics | 2 | 16.0 |
Drug Resistance | 16 | 2.0 |
Enzyme Inhibitors/*pharmacology | 5 | 0.0 |
Etoposide/pharmacology | 2 | 1.0 |
RNA, Messenger/*metabolism | 4 | 0.0 |
*Point Mutation | 4 | 0.0 |
Alkylation | 7 | 10.0 |
Base Pair Mismatch | 5 | 3.0 |
CHO Cells | 10 | 0.0 |
Cricetulus | 2 | 0.0 |
*DNA Glycosylases | 3 | 4.0 |
DNA-(Apurinic or Apyrimidinic Site) Lyase | 4 | 6.0 |
Deoxyribonuclease IV (Phage T4-Induced) | 4 | 8.0 |
Hamsters | 14 | 0.0 |
Methylation | 20 | 3.0 |
Mice, Knockout | 4 | 0.0 |
Mutagenesis | 3 | 0.0 |
Mutagens/toxicity | 2 | 5.0 |
O(6)-Methylguanine-DNA Methyltransferase/physiology | 2 | 66.0 |
Alkylating Agents/*toxicity | 2 | 16.0 |
Carmustine/toxicity | 4 | 57.0 |
Cells, Cultured | 8 | 0.0 |
Colony-Forming Units Assay | 2 | 0.0 |
*DNA Damage | 7 | 1.0 |
Drug Resistance/*genetics | 3 | 6.0 |
Hematopoietic Stem Cells/*drug effects/enzymology | 2 | 50.0 |
Lomustine/toxicity | 2 | 100.0 |
Moloney murine leukemia virus/genetics | 2 | 6.0 |
Nimustine/toxicity | 3 | 100.0 |
Retroviridae/*genetics | 5 | 3.0 |
O(6)-Methylguanine-DNA Methyltransferase/*biosynthesis | 4 | 66.0 |
Time Factors | 18 | 0.0 |
*Carcinogens | 2 | 6.0 |
DNA Adducts | 2 | 2.0 |
Exons | 5 | 0.0 |
Genes, ras/genetics | 2 | 1.0 |
Heterozygote | 2 | 0.0 |
Carcinoma/*genetics | 2 | 1.0 |
Genes, p53/genetics | 3 | 1.0 |
Stomach Neoplasms/*genetics | 2 | 1.0 |
Antineoplastic Agents/pharmacology | 7 | 1.0 |
Drug Resistance, Neoplasm/*genetics | 6 | 6.0 |
*Genes, MDR | 3 | 8.0 |
Microsatellite Repeats | 3 | 0.0 |
Oligodendroglioma/*genetics | 2 | 20.0 |
Chromosome Aberrations | 2 | 0.0 |
Oncogenes | 2 | 0.0 |
Drug Resistance, Neoplasm/physiology | 3 | 20.0 |
RNA, Catalytic/*metabolism | 2 | 13.0 |
Methylnitrosourea | 3 | 33.0 |
Antineoplastic Agents, Alkylating/pharmacology | 3 | 11.0 |
Chromosome Mapping | 3 | 0.0 |
Genome, Human | 2 | 0.0 |
Antineoplastic Agents, Alkylating/therapeutic use | 3 | 13.0 |
Brain Neoplasms/*drug therapy | 2 | 25.0 |
Carmustine/analogs & derivatives/*therapeutic use | 2 | 100.0 |
Glioma/*drug therapy | 3 | 33.0 |
Antineoplastic Agents/therapeutic use | 4 | 1.0 |
Combined Modality Therapy | 6 | 0.0 |
Nimustine/therapeutic use | 4 | 100.0 |
Neoplasms/*genetics | 2 | 0.0 |
Age Factors | 2 | 0.0 |
Brain/*enzymology | 3 | 1.0 |
Brain Neoplasms/*enzymology | 5 | 35.0 |
*Acid Anhydride Hydrolases | 3 | 1.0 |
Genes, p16/genetics | 2 | 9.0 |
Isoenzymes/metabolism | 2 | 0.0 |
DNA/metabolism | 9 | 0.0 |
Neoplasm Metastasis | 3 | 0.0 |
Treatment Outcome | 7 | 0.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/*genetics | 3 | 15.0 |
DNA, Neoplasm/genetics/metabolism | 3 | 3.0 |
Polymerase Chain Reaction/methods | 9 | 0.0 |
O(6)-Methylguanine-DNA Methyltransferase/biosynthesis/*genetics | 6 | 100.0 |
Cadherins/genetics | 8 | 14.0 |
Risk Factors | 6 | 0.0 |
Tissue Inhibitor of Metalloproteinase-3/genetics | 5 | 35.0 |
Genes, Tumor Suppressor/*physiology | 4 | 3.0 |
Blotting, Southern | 7 | 0.0 |
Dacarbazine/*analogs & derivatives/*pharmacology | 2 | 50.0 |
Dose-Response Relationship, Drug | 11 | 0.0 |
*Genetic Vectors | 2 | 0.0 |
Models, Genetic | 7 | 0.0 |
Dacarbazine/*toxicity | 2 | 100.0 |
Guanine/analogs & derivatives/metabolism | 3 | 20.0 |
Rats | 14 | 0.0 |
Rats, Sprague-Dawley | 4 | 0.0 |
Amino Acid Sequence | 14 | 0.0 |
Molecular Sequence Data | 41 | 0.0 |
Molecular Weight | 4 | 0.0 |
Serine Endopeptidases/metabolism | 2 | 1.0 |
Antineoplastic Agents, Alkylating/pharmacology/*therapeutic use | 2 | 66.0 |
Disease-Free Survival | 5 | 0.0 |
Gene Expression Regulation, Enzymologic/drug effects | 2 | 1.0 |
*Endonucleases | 3 | 3.0 |
*Polymorphism, Single Nucleotide | 2 | 0.0 |
Sequence Analysis, DNA | 5 | 0.0 |
Protein Biosynthesis | 5 | 0.0 |
Cell Cycle/genetics | 2 | 1.0 |
DNA Repair | 31 | 4.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 16 | 0.0 |
Cell Cycle | 5 | 0.0 |
Enzyme Activation | 2 | 0.0 |
Prospective Studies | 4 | 0.0 |
Retrospective Studies | 5 | 0.0 |
Antineoplastic Agents, Alkylating/*pharmacology | 9 | 23.0 |
Gene Targeting | 2 | 0.0 |
Nitrogen Mustard Compounds/*pharmacology | 3 | 37.0 |
Sister Chromatid Exchange/drug effects | 5 | 26.0 |
Cell Line, Tumor | 5 | 0.0 |
*CpG Islands | 10 | 12.0 |
Down-Regulation | 7 | 0.0 |
Adenoma/genetics | 3 | 6.0 |
Genes, ras/*genetics | 3 | 3.0 |
Guanine/metabolism | 2 | 11.0 |
Antimetabolites, Antineoplastic/*pharmacology | 2 | 2.0 |
Fluorouracil/*pharmacology | 2 | 5.0 |
Forecasting | 2 | 0.0 |
*Gene Expression Profiling | 4 | 0.0 |
*Models, Theoretical | 2 | 3.0 |
*Oligonucleotide Array Sequence Analysis | 2 | 1.0 |
Predictive Value of Tests | 9 | 0.0 |
Regression Analysis | 2 | 0.0 |
Stomach Neoplasms/*drug therapy/*genetics | 2 | 100.0 |
Cell Division/drug effects | 4 | 0.0 |
*DNA-Binding Proteins | 7 | 0.0 |
Enzyme Stability/genetics | 2 | 7.0 |
Methylnitronitrosoguanidine/pharmacology | 6 | 25.0 |
*Polymorphism, Genetic | 5 | 0.0 |
Precipitin Tests | 5 | 0.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
Brain Neoplasms/*genetics/pathology | 3 | 4.0 |
Nimustine/pharmacology | 5 | 71.0 |
RNA, Messenger/analysis | 10 | 0.0 |
Tumor Cells, Cultured/drug effects | 5 | 0.0 |
Brain/metabolism | 2 | 0.0 |
Carmustine/*pharmacology | 11 | 57.0 |
Drug Synergism | 10 | 0.0 |
Glioblastoma/*genetics/metabolism | 2 | 16.0 |
Antineoplastic Agents/*toxicity | 4 | 6.0 |
Tumor Cells, Cultured/*drug effects | 2 | 4.0 |
O(6)-Methylguanine-DNA Methyltransferase/*antagonists & inhibitors | 3 | 50.0 |
Drug Resistance, Multiple/*genetics | 2 | 3.0 |
Enzyme Stability | 3 | 1.0 |
*Gene Therapy | 2 | 0.0 |
Guanine/*analogs & derivatives/pharmacology | 10 | 32.0 |
K562 Cells | 2 | 0.0 |
Genes, p53 | 5 | 1.0 |
Brain Neoplasms/pathology | 2 | 10.0 |
Carmustine/pharmacology | 4 | 18.0 |
Transduction, Genetic | 2 | 0.0 |
Carcinogens | 4 | 5.0 |
Hypersensitivity | 2 | 16.0 |
L-Lactate Dehydrogenase/analysis | 2 | 5.0 |
Codon/genetics | 3 | 0.0 |
Guanine/*analogs & derivatives/metabolism | 6 | 24.0 |
*Mutagenesis | 2 | 3.0 |
O(6)-Methylguanine-DNA Methyltransferase/*biosynthesis/genetics | 2 | 66.0 |
Organ Specificity | 2 | 0.0 |
Spleen/enzymology | 2 | 6.0 |
Alkylating Agents/pharmacology | 5 | 14.0 |
Alkylating Agents/*pharmacology | 4 | 21.0 |
Drug Resistance, Neoplasm/genetics | 3 | 4.0 |
Nitroso Compounds/therapeutic use | 2 | 100.0 |
Antineoplastic Agents, Alkylating/*therapeutic use | 4 | 22.0 |
Brain Neoplasms/*drug therapy/*enzymology | 3 | 100.0 |
Glioma/*drug therapy/*enzymology | 4 | 100.0 |
Alkyl and Aryl Transferases/*metabolism | 2 | 66.0 |
Crosses, Genetic | 2 | 0.0 |
Lung/*enzymology | 2 | 3.0 |
DNA-Binding Proteins/*genetics | 3 | 0.0 |
Etoposide/toxicity | 2 | 11.0 |
Neoplasm Proteins/*genetics | 4 | 0.0 |
Proto-Oncogene Proteins/*genetics | 2 | 0.0 |
*Transcription, Genetic | 5 | 0.0 |
Genes, ras | 3 | 1.0 |
Retroviridae | 3 | 4.0 |
DNA Footprinting | 2 | 0.0 |
Dexamethasone/*pharmacology | 2 | 0.0 |
Sequence Deletion | 3 | 0.0 |
Cell Differentiation | 2 | 0.0 |
DNA, Complementary/*genetics | 2 | 0.0 |
*Gene Transfer Techniques | 2 | 0.0 |
Brain Neoplasms/*drug therapy/pathology | 2 | 25.0 |
Guanine/analogs & derivatives/pharmacology | 4 | 30.0 |
Methyl Methanesulfonate/pharmacology | 2 | 5.0 |
Streptozocin/*pharmacology | 3 | 75.0 |
3T3 Cells | 5 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Methylnitronitrosoguanidine/toxicity | 4 | 40.0 |
Recombinant Proteins/biosynthesis | 3 | 0.0 |
Vincristine/toxicity | 2 | 28.0 |
Ependymoma/enzymology | 2 | 66.0 |
Medulloblastoma/enzymology | 2 | 50.0 |
Apoptosis/genetics | 2 | 0.0 |
*Models, Genetic | 2 | 1.0 |
Mutagens/pharmacology | 3 | 7.0 |
Sister Chromatid Exchange/*drug effects | 3 | 10.0 |
Carmustine/*therapeutic use | 2 | 50.0 |
Glioblastoma/drug therapy/*enzymology/*mortality | 2 | 100.0 |
Nitrosourea Compounds/*pharmacology | 3 | 42.0 |
*Gene Expression Regulation, Enzymologic | 6 | 1.0 |
Antibodies | 2 | 0.0 |
Lung Neoplasms/*enzymology | 2 | 8.0 |
DNA Adducts/genetics | 2 | 40.0 |
Recombinant Proteins/biosynthesis/metabolism | 2 | 1.0 |
Antibodies, Monoclonal | 2 | 0.0 |
Binding Sites | 5 | 0.0 |
Cell Nucleus/metabolism | 4 | 0.0 |
Deoxyribonuclease I/metabolism | 2 | 1.0 |
Epitope Mapping | 3 | 1.0 |
Rabbits | 2 | 0.0 |
Antineoplastic Agents/adverse effects | 2 | 6.0 |
*Escherichia coli Proteins | 3 | 1.0 |
Colon/metabolism | 2 | 1.0 |
Colorectal Neoplasms/*genetics/pathology | 4 | 4.0 |
Substrate Specificity | 3 | 0.0 |
Tumor Cells, Cultured/drug effects/enzymology | 4 | 12.0 |
Chromatin/metabolism | 2 | 0.0 |
CpG Islands/*physiology | 2 | 18.0 |
Cytosine/metabolism | 3 | 8.0 |
Methyltransferases/*genetics | 27 | 26.0 |
O(6)-Methylguanine-DNA Methyltransferase | 110 | 65.0 |
T-Lymphocytes | 2 | 0.0 |
Biological Markers | 2 | 0.0 |
Bone Marrow Cells | 2 | 0.0 |
Bone Marrow Transplantation | 3 | 1.0 |
Methyltransferases/*genetics/metabolism | 6 | 15.0 |
Chromatin/*metabolism | 2 | 1.0 |
Gene Expression/drug effects | 3 | 0.0 |
Methyltransferases/genetics/*metabolism | 7 | 23.0 |
Restriction Mapping | 10 | 0.0 |
RNA, Messenger/*genetics | 2 | 0.0 |
Antineoplastic Agents/chemistry/*pharmacology | 2 | 8.0 |
Methyltransferases/*antagonists & inhibitors | 2 | 15.0 |
China | 2 | 0.0 |
Gene Amplification | 2 | 0.0 |
Binding Sites/genetics | 2 | 0.0 |
DNA/*genetics | 3 | 0.0 |
Escherichia coli/enzymology/genetics | 2 | 3.0 |
Mutagenesis, Site-Directed | 4 | 0.0 |
Cell Compartmentation | 2 | 0.0 |
Protein Binding | 4 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 4 | 0.0 |
Cisplatin/administration & dosage | 4 | 1.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 2 | 0.0 |
Carmustine/*toxicity | 4 | 66.0 |
Methyltransferases/*metabolism | 19 | 27.0 |
Cell Nucleus/enzymology | 3 | 3.0 |
Liver/*enzymology | 2 | 0.0 |
Bronchoalveolar Lavage | 2 | 8.0 |
Sulfites/pharmacology | 2 | 6.0 |
Central Nervous System Neoplasms/*genetics | 3 | 21.0 |
Ependymoma/*genetics | 2 | 18.0 |
Methyltransferases/analysis/*metabolism | 2 | 66.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
Transcription Factor, Sp1/metabolism | 2 | 0.0 |
Antibodies, Monoclonal/immunology | 2 | 0.0 |
Recombinant Fusion Proteins/metabolism | 4 | 0.0 |
Codon | 3 | 0.0 |
L-Lactate Dehydrogenase/metabolism | 2 | 1.0 |
Lymphocytes/enzymology | 2 | 2.0 |
Pharmacogenetics | 2 | 1.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Antineoplastic Agents, Alkylating/*toxicity | 2 | 20.0 |
Deoxyguanosine/*analogs & derivatives/pharmacology | 2 | 33.0 |
Kinetics | 10 | 0.0 |
Methyltransferases/antagonists & inhibitors | 3 | 33.0 |
Methyltransferases/*physiology | 5 | 71.0 |
Multivariate Analysis | 2 | 0.0 |
Proportional Hazards Models | 2 | 0.0 |
Gene Transfer Techniques | 2 | 0.0 |
DNA Probes | 3 | 0.0 |
Glioma/enzymology | 2 | 33.0 |
Caspases/genetics | 3 | 12.0 |
In Vitro | 3 | 0.0 |
Reference Values | 5 | 0.0 |
Ethylnitrosourea/*analogs & derivatives/pharmacology | 2 | 66.0 |
Methyltransferases/antagonists & inhibitors/*metabolism | 3 | 33.0 |
Chemotherapy, Adjuvant | 2 | 0.0 |
Methyltransferases/genetics | 2 | 11.0 |
Neoplasm Recurrence, Local | 2 | 0.0 |
RNA, Neoplasm/metabolism | 2 | 2.0 |
Precancerous Conditions/*genetics/pathology | 2 | 10.0 |
Drug Administration Schedule | 2 | 0.0 |
DNA/analysis | 2 | 0.0 |
Nuclear Proteins/genetics | 3 | 1.0 |
Genes, Structural | 4 | 0.0 |
Cell Adhesion/physiology | 2 | 0.0 |
Colonic Neoplasms/drug therapy/enzymology | 2 | 66.0 |
Culture Media | 2 | 0.0 |
Drug Screening Assays, Antitumor | 4 | 1.0 |
Medulloblastoma/*drug therapy/*enzymology | 2 | 100.0 |
Brain Neoplasms/*enzymology/pathology | 2 | 25.0 |
Breast Neoplasms/*enzymology/pathology | 2 | 6.0 |
*Gene Expression | 4 | 0.0 |
*Genes, ras | 3 | 1.0 |
Cattle | 2 | 0.0 |
Astrocytoma/enzymology | 2 | 40.0 |
Carmustine/administration & dosage | 2 | 15.0 |
Streptozocin/administration & dosage | 2 | 33.0 |
Tumor Stem Cell Assay | 2 | 1.0 |
Clone Cells | 2 | 0.0 |
Methyltransferases/biosynthesis/*genetics | 3 | 60.0 |
Methylenetetrahydrofolate Reductase (NADPH2)/*genetics | 2 | 1.0 |
Neoplasm Proteins/genetics | 7 | 1.0 |
Polymorphism, Genetic | 2 | 0.0 |
Tumor Cells, Cultured/*enzymology | 2 | 25.0 |
Methyltransferases/metabolism | 2 | 6.0 |
Thioguanine/pharmacology | 2 | 11.0 |
Escherichia coli/enzymology | 2 | 3.0 |
Oligodeoxyribonucleotides | 2 | 0.0 |
Glioblastoma/*drug therapy | 2 | 28.0 |
Methyltransferases/*analysis | 3 | 30.0 |
DNA/*metabolism | 5 | 1.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Antibody Specificity | 2 | 0.0 |
Gene Expression/genetics | 3 | 1.0 |
Cell Survival | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Nucleic Acid Hybridization | 3 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
*Genotype | 2 | 0.0 |
Odds Ratio | 2 | 0.0 |
p14ARF Protein/genetics | 5 | 23.0 |
Genes, Structural, Neoplasm/genetics | 2 | 8.0 |
O(6)-Methylguanine-DNA Methyltransferase/*biosynthesis/*genetics | 2 | 100.0 |
Chronic Disease | 2 | 0.0 |
Retinoblastoma Protein/genetics | 2 | 5.0 |
Neoplasms/*genetics/*metabolism | 2 | 40.0 |
Japan | 3 | 0.0 |
Neoplasm Proteins/*biosynthesis | 2 | 2.0 |
Proto-Oncogene Proteins/*biosynthesis | 2 | 1.0 |
Adenoma/*genetics/pathology | 2 | 7.0 |
Adenomatous Polyposis Coli Protein/genetics | 2 | 12.0 |
Germ-Line Mutation | 2 | 0.0 |
Genes, APC | 2 | 2.0 |